Literature DB >> 8852410

Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity.

M Chiaramonte1, S Majori, T Ngatchu, M E Moschen, V Baldo, G Renzulli, I Simoncello, S Rocco, T Bertin, R Naccarato, R Trivello.   

Abstract

The efficacy of a 10 or 20 micrograms antigen load of HB recombinant vaccines is still being debated. A comparison of anti-HBs titres in two groups of healthy subjects vaccinated by the same schedule (0, 1 and 6 months) employing recombinant HB vaccines with different antigen loads, 20 micrograms (group A, 251 subjects) and 10 micrograms (group B, 256 subjects) was carried out. A seroprotection rate of 99.6 and 99.2% was observed for group A and group B, respectively, at the end of primary immunization. No statistically significant difference in seroprotection rate was observed. Group A showed significantly higher GMTs than group B for all age groups and for both sexes except for males above 25 years. The difference was more marked for younger age groups and for the female sex. These data support the higher immunogenicity of vaccine with 20 micrograms antigen load as compared to vaccines with 10 micrograms antigen load.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852410     DOI: 10.1016/0264-410x(95)00148-t

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  24 year outcomes of hepatitis B vaccination in Hangzhou, China.

Authors:  Jian Du; Yuyang Xu; Jun Wang; Shijun Liu; Yan Liu; Xiaoping Zhang; Erping Xu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Immune response to an indigenously developed r-hepatitis B vaccine in mixed population: study of an accelerated vaccination schedule.

Authors:  A Chowdhury; A Santra; C-M Habibullah; A-A Khan; J Karunakaramaiah; T-S-A Kishore; A-V-R Raju; S Lahiri
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

4.  Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.

Authors:  Zuzana Zelinkova; Evelien Bultman; Lauran Vogelaar; Cheima Bouziane; Ernst J Kuipers; C Janneke van der Woude
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 5.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Comparison of long-term immunogenicity (23 years) of 10 μg and 20 μg doses of hepatitis B vaccine in healthy children.

Authors:  Qian Wu; Gui-hua Zhuang; Xue-liang Wang; Tie-jun Hou; Dimpy P Shah; Xiao-li Wei; Li-rong Wang; Min Zhang
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

7.  The effects of increased dose of hepatitis B vaccine on mother-to-child transmission and immune response for infants born to mothers with chronic hepatitis B infection: a prospective, multicenter, large-sample cohort study.

Authors:  Xiaohui Zhang; Huaibin Zou; Yu Chen; Hua Zhang; Ruihua Tian; Jun Meng; Yunxia Zhu; Huimin Guo; Erhei Dai; Baoshen Zhu; Zhongsheng Liu; Yanxia Jin; Yujie Li; Liping Feng; Hui Zhuang; Calvin Q Pan; Jie Li; Zhongping Duan
Journal:  BMC Med       Date:  2021-07-13       Impact factor: 8.775

8.  Suitable hepatitis B vaccine for adult immunization in China.

Authors:  Linna Yang; Jun Yao; Jing Li; Yongdi Chen; Zheng-Gang Jiang; Jing-Jing Ren; Kai-Jin Xu; Bing Ruan; Shi-Gui Yang; Bing Wang; Tian-Sheng Xie; Qian Li
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.